Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial (ECLIPSE)
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring atherectomy, CAD, severe calcium, orbital atherectomy, minimum stent area
Eligibility Criteria
General Inclusion Criteria:
- Subject is 18 years of age or older.
Subject presents with:
- stable ischemic heart disease or
- acute coronary syndrome (NSTEMI or unstable angina), or
- stabilized recent STEMI (>48 hours prior to randomization procedure)
- Subject has signed the Institutional Review Board (IRB) or Ethics Committee (EC) approved ECLIPSE trial Informed Consent Form (ICF) prior to any trial related procedures.
General Exclusion Criteria
- Subject has a history of any cognitive or mental health status that would interfere with trial participation.
- Subject is participating in or has plans to participate in any other investigational drug or device trial that has not reached its primary endpoint.
- Subject is a female who is pregnant.
- Subject is receiving or scheduled to receive chemotherapy within thirty (30) days prior or any time after the randomization procedure.
- Subject has a life expectancy of ≤ 12 months.
- Subject has undergone any prior PCI in the target vessel or its branches 12 months prior to randomization.
- Subject has undergone a PCI procedure that is unsuccessful or with complications within 30 days prior to randomization, including during the randomization procedure.
- Any cardiac intervention or cardiac surgery planned within 12 months post randomization procedure aside from a potential planned staged PCI as part of the randomized treatment strategy.
- Subject has major valve disease and underwent intervention within 30 days prior to randomization.
- Subject has received a heart transplant.
Evidence of heart failure by at least one of the following (heart failure assessment is not required per protocol but must be reviewed prior to enrollment if data is available):
- Most recent LVEF ≤25%, or
- Current heart failure defined as dyspnea at rest (NYHA class IV assessed day of procedure), or
- Killip class ≥2 (post STEMI patients)
- Planned use in the randomized lesion(s) of a bare metal stent (BMS), bioresorbable scaffold (BRS), non-stent treatment only.
- Subject has a known sensitivity to contrast media, which cannot be adequately pre-medicated.
- Subject has a relative or absolute contraindication to dual antiplatelet therapy or (for patients with atrial fibrillation) single antiplatelet therapy (P2Y12 inhibitor preferred) with an anticoagulant for at least 6 months after PCI.
- Subject has a history of a stroke or transient ischemic attack (TIA) within six (6) months prior to randomization, or any permanent neurologic deficit.
- Subject has a history of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary.
- Subject has evidence of an active infection on the day of the randomization procedure requiring oral or intravenous antibiotics.
- Subject with known allergy to atherectomy lubricant components including soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide.
Sites / Locations
- University of Alabama - Birmingham
- Mercy Gilbert Medical Center
- St. Luke's Medical Center
- Arizona Heart Hospital
- Yavapai Regional Medical Center
- Arkansas Heart Hospital
- University of California - San Diego
- Cedars-Sinai Medical Center
- Ronald Reagan UCLA Medical Center
- San Francisco VA Medical Center
- Denver VA Medical Center
- Colorado Heart and Vascular
- Yale New Haven Hospital
- Medstar Washington Hospital Center
- The Cardiac & Vascular Institute Research Foundation
- Memorial Regional Hospital
- UF Health Jacksonville
- Heart Institute at Largo
- AdventHealth Ocala
- Florida Hospital Orlando
- Palm Beach Gardens Medical Center
- Tallahassee Research Institute
- St. Joseph's Hospital
- Atlanta VA Medical Center
- Piedmont Atlanta Hospital
- Northeast Georgia Medical Center
- University of Illinos - Chicago
- Loyola University Medical Center
- Advocate Christ Medical Center
- Indiana University
- St. Vincent Heart of Indiana
- Community Hospital
- Reid Health
- Genesis Medical Center
- Iowa Heart Center
- The University of Kansas Medical Center
- U of L Health
- Baton Rouge General Medical Center
- Cardiovascular Institute of the South
- Lafayette General Medical Center
- Ochsner Medical
- Maine Medical Center
- Massachusetts General Hospital
- Brigham and Women's Hospital
- Lahey Clinic
- University of Massachusetts Worcester
- University of Michigan
- Detroit Medical Center
- Henry Ford Hospital
- Ascension St. John Hospital and Medical Center
- Metropolitan Cardiology Consultants
- Essentia Health
- Fairview Southdale Hospital
- Minneapolis Heart Institute
- CentraCare Heart & Vascular Center
- Forrest General - Hattiesburg Clinic
- Stern Cardiovascular
- VA St. Louis Healthcare System
- Barnes-Jewish Hospital
- St. Louis University
- Deborah Heart and Lung Medical Center
- Hackensack University Medical Center
- Morristown Medical Center
- Newark Beth Israel Medical Center
- New Mexico Heart Institute
- St. Peter's Hospital
- Montefiore-Einstein Medical Center
- New York University School of Medicine
- Columbia University Medical Center / New York-Presbyterian Hospital
- Northwell Health
- Hudson Valley Cardiovascular Practice, PC
- St. Francis Hospital
- University of North Carolina
- Duke University Medical Center
- Durham VA Medical Center
- WakeMed
- Wake Forest Baptist Health
- Mercy Health West Hospital
- University Hospital Cleveland
- Cleveland Clinic
- Riverside Methodist Hospital/Ohio Health
- Premier Health Specialists
- Oklahoma Heart Hospital - South Campus
- Oklahoma Heart Hospital
- St. John's Health System
- Penn Presbyterian Medical Center
- Einstein Medical Center
- Allegheny General Hospital
- Rhode Island Hospital
- Sanford Heart Hospital
- Wellmont CVA Heart Institute
- Methodist University Hospital
- Centennial Medical Center
- Methodist Health
- Dallas VA Medical Center
- Houston Methodist
- University of Texas Health Science Center at Houston
- University of Texas Health Science Center at San Antonio
- Sentara Cardiovascular
- Providence Regional Medical Center Everett
- Virginia Mason Medical Center
- Swedish Medical Center
- Charleston Area Medical Center
- Aurora St. Luke's Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Orbital Atherectomy (OA)
Conventional Balloon Angioplasty
The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.